Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 10:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 51 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Quinidine Gluconate Clear all
Terminated Phase 3 Interventional Results available

Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

NCT02446132
View directory record Official record
Conditions
Agitation in Patients With Dementia of the Alzheimer's Type
Interventions
AVP-786
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
1,197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
171
States / cities
Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 103 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Sep 12, 2026, 10:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study Comparing AVP-786 With AVP-923

NCT02336347
View directory record Official record
Conditions
Healthy Volunteer
Interventions
AVP-786, AVP-923
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Sep 12, 2026, 10:03 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients

NCT01767129
View directory record Official record
Conditions
Dyskinesia, Parkinson's Disease
Interventions
AVP-923-45, Placebo
Drug
Lead sponsor
Avanir Pharmaceuticals
Industry
Eligibility
30 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Chicago, Illinois • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Sep 12, 2026, 10:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Imlunestrant (LY3484356) in Female Healthy Participants

NCT05444556
View directory record Official record
Conditions
Healthy
Interventions
Imlunestrant, Repaglinide, Omeprazole, Dextromethorphan, Quinidine, Rosuvastatin, Digoxin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
113 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
3
States / cities
Cypress, California • South Miami, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Sep 12, 2026, 10:03 PM EDT
Completed Phase 2 Interventional Results available

Nuedexta for the Prevention and Modification of Disease Progression in Episodic Migraine

NCT02176018
View directory record Official record
Conditions
Episodic Migraine
Interventions
Dextromethorphan and quinidine, Placebo
Drug
Lead sponsor
Cady, Roger, M.D.
Individual
Eligibility
18 Years to 65 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
5
States / cities
Rockford, Illinois • Ridgeland, Mississippi • City of Saint Peters, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2018 · Synced Sep 12, 2026, 10:03 PM EDT
Terminated Phase 2Phase 3 Interventional

Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of Schizophrenia

NCT03896945
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, AVP-786
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
61
States / cities
Little Rock, Arkansas • Anaheim, California • Bellflower, California + 53 more
Source: ClinicalTrials.gov public record
Updated May 23, 2024 · Synced Sep 12, 2026, 10:03 PM EDT
Completed Phase 3 Interventional

Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter)

NCT00056524
View directory record Official record
Conditions
Alzheimer's Disease, Stroke, Parkinson's Disease, Traumatic Brain Injury
Interventions
AVP-923
Drug
Lead sponsor
Avanir Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
39
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Sep 12, 2026, 10:03 PM EDT
Completed Phase 2 Interventional

Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

NCT02153502
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
AVP-786 (d6-dextromethorphan hydrobromide and quinidine sulfate combination), Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
32
States / cities
Birmingham, Alabama • Bellflower, California • Costa Mesa, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 12, 2026, 10:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-drug Interaction Study Between EDP-305, Fluconazole and Quinidine in Healthy Volunteers

NCT03610945
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
Fluconazole, Quinidine, EDP-305
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 4, 2018 · Synced Sep 12, 2026, 10:03 PM EDT
Completed Phase 2 Interventional Results available

Nuedexta in Treatment-Resistant Major Depression

NCT01882829
View directory record Official record
Conditions
Major Depressive Disorder, Treatment Resistant
Interventions
dextromethorphan/quinidine
Drug
Lead sponsor
James Murrough
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 10, 2018 · Synced Sep 12, 2026, 10:03 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Evaluating the Efficacy of Dextromethorphan/Quinidine in Treating Irritability in Huntington's Disease

NCT03854019
View directory record Official record
Conditions
Huntington Disease, Irritability
Interventions
Dextromethorphan/quinidine 20mg/10mg (DM/Q 20mg/10mg), Placebo
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 4, 2024 · Synced Sep 12, 2026, 10:03 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Participants With Dementia of the Alzheimer's Type

NCT02442778
View directory record Official record
Conditions
Agitation in Participants With Dementia of the Alzheimer's Type
Interventions
AVP-786-18, Placebo, AVP-786-28, AVP-786-42.63
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
522 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
79
States / cities
Chandler, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 55 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2022 · Synced Sep 12, 2026, 10:03 PM EDT
Terminated Phase 2 Interventional Results available

Safety, Tolerability and Efficacy of AVP-786 for the Treatment of Disinhibition

NCT02534038
View directory record Official record
Conditions
Disinhibition Syndrome
Interventions
AVP-786, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Sep 12, 2026, 10:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of P-glycoprotein Inhibition on Lenalidomide Pharmacokinetics in Healthy Males

NCT01712828
View directory record Official record
Conditions
Healthy
Interventions
Lenalidomide, Quinidine, Temsirolimus, Diphenhydramine
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 7, 2019 · Synced Sep 12, 2026, 10:03 PM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Residual Schizophrenia

NCT02477670
View directory record Official record
Conditions
Schizophrenia
Interventions
AVP-786, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
17
States / cities
Cerritos, California • Garden Grove, California • National City, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Sep 12, 2026, 10:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Pharmacokinetics of AZD2389 in Healthy Participants When Administered Alone and in Combination With Quinidine

NCT06974565
View directory record Official record
Conditions
Advanced Chronic Liver Disease, Healthy Participants
Interventions
AZD2389, Quinidine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 24, 2025 · Synced Sep 12, 2026, 10:03 PM EDT
Terminated Phase 3 Interventional Results available

AV Node Ablation and Pacemaker Therapy Compared to Drug Therapy for Atrial Fibrillation - Pilot Study

NCT00589303
View directory record Official record
Conditions
Atrial Fibrillation, Heart Failure
Interventions
FDA approved rate and rhythm control drugs, AV Node ablation and device implant
Drug · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
65 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
5
States / cities
Scottsdale, Arizona • Evansville, Indiana • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2013 · Synced Sep 12, 2026, 10:03 PM EDT
Terminated Phase 4 Interventional

Nuedexta in the Treatment of Pseudobulbar Affect in Patients With Alzheimer's Disease

NCT01832350
View directory record Official record
Conditions
Alzheimer's Disease, Pseudobulbar Affect (PBA)
Interventions
Nuedexta (20/10)
Drug
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
55 Years to 90 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 28, 2019 · Synced Sep 12, 2026, 10:03 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Volunteers to Investigate the Effects of Quinidine on the Pharmacokinetics of NKTR-118

NCT01533155
View directory record Official record
Conditions
Drug Induced Constipation
Interventions
Nektar 118, Quinidine, Quinidine placebo, Morphine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
214 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2014 · Synced Sep 12, 2026, 10:03 PM EDT
Terminated Phase 3 Interventional Results available

Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

NCT04408755
View directory record Official record
Conditions
Agitation in Patients With Dementia of the Alzheimer's Type
Interventions
AVP-786, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
45
States / cities
Fort Smith, Arkansas • La Jolla, California • Los Angeles, California + 33 more
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Sep 12, 2026, 10:03 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS

NCT00573443
View directory record Official record
Conditions
Pseudobulbar Affect (PBA)
Interventions
dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg, dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg, Placebo
Drug
Lead sponsor
Avanir Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
45
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Anaheim, California + 39 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Sep 12, 2026, 10:03 PM EDT
Completed Phase 2 Interventional Results available

Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Neurobehavioral Disinhibition Including Aggression, Agitation, and Irritability in Participants With Traumatic Brain Injury

NCT03095066
View directory record Official record
Conditions
Neurobehavioral Disinhibition
Interventions
Placebo, AVP-786-28, AVP-786-42.63
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
54
States / cities
Tuscaloosa, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Sep 12, 2026, 10:03 PM EDT
Completed Phase 4 Interventional Results available

Safety, Tolerability and Effectiveness of Nuedexta in the Treatment of Pseudobulbar Affect (PBA)

NCT01799941
View directory record Official record
Conditions
Pseudobulbar Affect (PBA), Stroke, Dementia, Traumatic Brain Injury (TBI)
Interventions
Nuedexta (DM 20 mg/Q 10 mg)
Drug
Lead sponsor
Avanir Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Pensacola, Florida
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Sep 12, 2026, 10:03 PM EDT
Terminated Phase 2 Interventional Results available

Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Intermittent Explosive Disorder

NCT03420222
View directory record Official record
Conditions
Intermittent Explosive Disorder
Interventions
AVP-786, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
9
States / cities
Gainesville, Florida • Atlanta, Georgia • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated May 23, 2022 · Synced Sep 12, 2026, 10:03 PM EDT